

Navigating the future with chronic kidney disease: towards patient-centred prognostic modelling Milders, J.

### Citation

Milders, J. (2025, November 20). *Navigating the future with chronic kidney disease: towards patient-centred prognostic modelling*. Retrieved from https://hdl.handle.net/1887/4283312

Version: Publisher's Version


Licence agreement concerning inclusion of doctoral

License: thesis in the Institutional Repository of the University

of Leiden

Downloaded from: <a href="https://hdl.handle.net/1887/4283312">https://hdl.handle.net/1887/4283312</a>

**Note:** To cite this publication please use the final published version (if applicable).



## LIVING WITH CHRONIC KIDNEY DISEASE: FUTURE PERSPECTIVES AND PROGNOSTIC NEEDS OF PATIENTS - A QUALITATIVE STUDY

Jet Milders, Yvette Meuleman, Chava L. Ramspek, Willem Jan W. Bos, Wieneke M. Michels, Y. de Jong, Friedo W. Dekker, Merel van Diepen

Revised manuscript published in BMC Nephrology. 2025;26(1):301

### **Abstract**

**Background.** Individualized prognostic information can help patients with chronic kidney disease (CKD) understand and prepare for their future, facilitating informed shared decision-making. While research has indicated that CKD patients want more information about their future, little is known about their specific prognostic needs. Therefore, this study aims to explore how patients with CKD perceive their future and what their prognostic needs are.

**Methods**. A survey was constructed with patient representatives, and distributed amongst adult CKD patients (all stages) through patient associations and healthcare professionals in two Dutch hospitals. Following an exploratory-descriptive qualitative approach, answers to four open-ended questions of 163 patients were analysed inductively using thematic analysis.

Results. Patients described a wide range of emotions when thinking about their future with CKD, including negative emotions like uncertainty, fear, sadness, and to a lesser extent, anger. However, some patients maintained emotional neutrality or described experiencing positive emotions like calmness, hope and trust. Additionally, patients had diverse prognostic needs, focusing on different topics like CKD treatment, kidney disease progression, self-management, symptoms, life expectancy and life participation. While most patients wanted more personalized prognostic information on these topics, some felt like they were already sufficiently informed about their future or preferred to live in the present moment.

**Conclusions**. Our findings show that CKD patients experience a wide variety of emotions regarding their future. Despite conversations about their future taking place in nephrological practice, there remain unmet questions regarding the future. These results underline the importance of adopting a personalized approach when discussing the future with CKD patients, acknowledging and taking the diverse emotional responses and individual preferences into account.

### Introduction

Living with chronic kidney disease (CKD) comes with a high disease burden, as patients can experience many symptoms like pain, pruritus, fatigue, mental- and sexual problems. (1-8) These symptoms can seriously disrupt patients' daily (social) activities and diminish their quality of life. In advanced CKD stages, treatment burden increases as patients often require intensive treatments, and are confronted with a heightened risk of adverse outcomes like hospitalization and death. (9-12) Faced with these challenges, CKD patients often experience uncertainty regarding their prognosis, and feelings of hopelessness and fear. (13)

The CKD course varies for every patient, making it difficult to foresee the disease impact on patients' lives in the future. Prognostic information tailored to the individual patient could provide insight into what to expect, and when these outcomes may occur, providing reassurance and time to prepare for the future. (14, 15) Additionally, well-informed patients are essential for shared-decision making, for example when considering different treatment options and the impact each option could have on their future.

Literature shows that patients desire more prognostic information earlier on in their disease trajectory. (13, 14, 16) However, knowledge about the specifics of their prognostic needs is lacking. Our previous quantitative study confirmed that patients with CKD desire more prognostic information about their future and about which topics (e.g. kidney function, energy levels and quality of life). (17) Building on these findings, we now seek to obtain an in-depth understanding of the reasons and stories behind these prognostic needs, the broader context in which they arise, and patients' emotions regarding their future. To achieve this, we qualitatively analysed the answers to the open-ended survey questions, aiming to explore two research questions: 1) How do patients with CKD view their future? and 2) What are the prognostic needs of patients regarding their future with CKD?

### Methods

This qualitative study uses an exploratory-descriptive approach, aimed to gain a deeper understanding of patients' experiences, perspectives, and meanings without predefined hypotheses. (18, 19) To ensure transparent reporting, we followed the Checklist for Reporting of Survey Studies (CROSS; Table S1 (20)) and where applicable, the Consolidated criteria for reporting qualitative studies (COREQ). (21)

### **Ethics**

This study was not subject to the Medical Research Involving Human Subjects Acts (WMO) as declared by the scientific committee of the department of Clinical Epidemiology at Leiden University Medical Center (LUMC) in The Netherlands. (22)

### Survey development and testing

A survey was constructed by an expert panel of researchers (JM, CLR, FWD, MvD) and nephrologists (WJWB, WMM) with experience in surveys, patient-reported outcomes, qualitative and prognostic research; and by patient representatives from the Dutch Kidney Patients Association (NVN) to ensure comprehensibility of the survey. (23) Castor Electronic Data Capture System was used for the online survey. A paper version was constructed to allow patients without internet access to participate. These surveys were manually added. During a two-phase pilot, the survey was tested in collaboration with NVN-volunteers (Supplementary Materials). The final survey contained questions on 1) demographics, 2) considerations about the future, and 3) prognostic needs. See Supplementary Materials for the full survey (translated from Dutch to English) and accompanying informational letter. Answers to four open-ended questions were analysed: A) What emotions do you experience when you think about your future with CKD?; B) Have you ever discussed your future with CKD with your treating physician? If yes, could you elaborate on that conversation?; C) What would you like to know about your future with CKD?; and D) If you think back to a year or two ago, what would you have wanted to know about your life with CKD that you know now?. Answers to question A were used to answer RQ1 "How do patients with CKD view their future?": questions C and D were used to answer RQ2 "What are the prognostic needs of patients regarding their future with CKD?", and question B was used to provide contextual information about current prognostic information provision.

### Study population and recruitment

All adult patients with CKD could participate, including those receiving KRT (dialysis or transplantation). We used convenience and purposive sampling, first deploying the survey through regional and national kidney patients associations (Diavaria and NVN. Since these sources mainly reached transplanted patients, the survey was also distributed at two Dutch hospitals (LUMC and Sint Antonius Hospital Nieuwegein) via nephrologists, nurse practitioners and one researcher (JM) to reach a more diverse and representative sample of the Dutch CKD population.

### Data collection and analysis

Patients completed the survey between October 17th 2022 and March 13th 2023. Surveys were gathered anonymously and duplicates (i.e. patients that started the survey multiple times) were removed. Questions were analysed using available case analysis, as completing open-ended questions was optional. Answers were analysed inductively following all six phases of thematic analysis: 1) familiarization with data, 2) coding, 3) searching for themes, 4) reviewing themes, 5) defining and naming themes, and 6) writing up. (24-26) Coding was performed by one researcher (JM), and coding strategies and themes were discussed with two other researchers (YM, MvD). Illustrative quotes were selected and translated from Dutch to English using back translation. Analyses were performed using Atlas.ti (Atlas, Berlin, v8.3.0- 2024-07-29).

### **Results**

### Response and participant characteristics

Through the patient organizations, 530 patients were contacted of which 108 (20.4%) completed the survey fully and 10 individuals (1.9%) partially. A total of 16 patients from LUMC completed the survey, and 28 complete and 1 partial survey(s) were filled in at the Sint Antonius Hospital. In total, six duplicates were removed. Open-ended question A, B, C and D (see Methods) were filled in by 137 (84.1%), 58 (35.6%), 131 (80.4%) and 125 (76.7%) patients, respectively.

In Table 1, participant characteristics are presented. Approximately half of the patients were female (50.9%), and the mean age was 63.9 years (SD 12.0). The majority of patients had undergone a kidney transplantation (56.4%), 16.0% was receiving dialysis, and 27.6% had CKD without receiving KRT.

Table 1. General characteristics of patients

|                                                              | Total<br>(n = 163) |
|--------------------------------------------------------------|--------------------|
| Patient recruitment source, n (%)                            | (11 – 103)         |
| National Dutch Kidney Patients Association (NVN)             | 100 (61.3%)        |
| Local Kidney Patients Association Hollands-midden (Diavaria) | 18 (11.0%)         |
| Leiden University Medical Center                             | 16 (9.8%)          |
| Sint Antonius Hospital Nieuwegein                            | 29 (17.8%)         |
| Age (mean, SD)                                               |                    |
|                                                              | 63.9 (12.0)        |
| Gender (female, n (%))                                       | 83 (50.9%)         |
| CKD patients without KRT                                     | 45 (27.6%)         |
| Dialysis modality/type, n (%)                                | 26 (16.0%)         |
| Haemodialysis in hospital                                    | 24 (92.3%)         |
| Haemodialysis at home                                        | 1 (3.8%)           |
| Peritoneal dialysis                                          | 1 (3.8%)           |
| Kidney transplantation, n (%)                                | 92 (56.4%)         |
| Education level, n (%)*                                      |                    |
| Low                                                          | 41 (25.2%)         |
| Medium                                                       | 36 (22.1%)         |
| High                                                         | 84 (51.5%)         |
| Other                                                        | 1 (0.6%)           |
| Living situation, n (%)                                      |                    |
| Alone                                                        | 35 (21.5%)         |
| Together with a partner                                      | 114 (69.9%)        |
| Child(ren) living at home                                    | 27 (16.6%)         |
| Care facility                                                | 3 (1.8%)           |
| Other**                                                      | 4 (2.5%)           |

| Cause of kidney disease, n (%)                                 |             |
|----------------------------------------------------------------|-------------|
| Diabetes mellitus                                              | 11 (6.7%)   |
| Vascular disease                                               | 15 (9.2%)   |
| Glomerulonephritis                                             | 16 (9.8%)   |
| Pyelonephritis, kidney damage by medication or nephrolithiasis | 9 (5.5%)    |
| Polycystic kidney disease                                      | 35 (21.5%)  |
| Autoimmune disease                                             | 16 (9.8%)   |
| Cancer                                                         | 3 (1.8%)    |
| Unknown                                                        | 31 (19.0%)  |
| Other                                                          | 27 (16.6%)  |
| Self-reported kidney function (eGFR), n (%)                    |             |
| >60 ml/min/1.73 m <sup>2</sup>                                 | 30 (18.4%)  |
| 45-59 ml/min/1.73 m <sup>2</sup>                               | 33 (20.2%)  |
| 30-44 ml/min/1.73 m <sup>2</sup>                               | 32 (19.6%)  |
| 15-29 ml/min/1.73 m <sup>2</sup>                               | 25 (15.3%)  |
| <15 ml/min/1.73 m <sup>2</sup>                                 | 30 (18.4%)  |
| Unknown                                                        | 13 (8.0%)   |
| Time since CKD diagnosis, n (%)                                |             |
| 0-4 years                                                      | 17 (10.4%)  |
| 5-10 years                                                     | 25 (15.3%)  |
| >10 years                                                      | 121 (74.2%) |

Some questions allowed multiple answers, meaning that percentages may add up to more than 100%.

<sup>\*</sup>Education levels were categorized based on the International Standard Classification of Education (ISCED) (48)

<sup>\*\*</sup>Patients that chose "Other" lived with parent(s), a housemate or spent the weekends with a longdistance partner.

### HOW DO PATIENTS WITH CKD VIEW THEIR FUTURE? (RQ1)

Three themes emerged and will be discussed below, with corresponding subthemes and illustrative quotes (see Figure 1 for a visual representation and Table 2 for additional quotes).

### Navigating an uncertain future and emotional challenges

Patients described a range of negative emotions, such as uncertainty, fear, and sadness. A predominant feeling was a profound sense of uncertainty regarding the future. Many patients reported a general uncertainty of what awaits:

I don't know what lies ahead for me. (Man, CKD without KRT, 88y)

For other patients the uncertainty related to specific topics. For example, they wondered if and when they will need dialysis (again) or worried about the longevity of their donor kidney. Another common feeling was a general fear for their unknown future. Some were afraid of needing dialysis in the future, while others feared death or a short lifespan due to CKD. Another fear described was regarding CKD progression itself, leading to more severe health problems, new medication regimens and side effects, and worsening of symptoms:

Fear that the disease will get worse, and I will become so tired again that I can't do anything. (Woman, KTx, 61y)

Notably, in some patients the worries motivated them to focus more on self-management:

Then I really worry about what my life will look like. At the same time, this motivates me to take optimal care of myself and to influence what I can to slow down disease progression. (Woman, CKD without KRT, 60y)

Sadness about future consequences of CKD was strongly present. For numerous patients it concerned an overall sadness without specific context. For others, sadness was related to their donor kidney potentially failing or the potential of having to undergo dialysis (again):

Sad, anxious, angry. For a few months now, I have known that I have chronic rejection and that I am highly immunized with 98.8%. Another transplant will not be possible easily. (Woman, KTx, 44y)

Other, less often described, negative emotions regarding their future included anger, helplessness, regret and vulnerability. For example, one participant stated feeling helpless and regretting having lived a life that was too stressful.

### Neutrality and emotional equilibrium

Many patients reported not experiencing any particularly negative or positive emotions when thinking about their future:

No specific emotions. I see the need to permanently adjust my lifestyle and the new physical limitations as a given. (Man, CKD without KRT, 50y)

For some patients, there appeared to be no reason for concern because their kidney function was currently stable.

### Positive emotional responses to the future with CKD

Patients shared an array of positive emotions such as calmness, hope and trust about their future with CKD.

A number of patients expressed a sense of calmness regarding their future. For example, patients described having accepted CKD and that they trust their body, bringing them a sense of calm:

Thinking is not something constructive or beneficial. It also affects the body's self-healing ability. Trust brings calmness. (Woman, dialysis, 75y)

Some patients attempted to achieve this calmness by having a positive outlook on their future, enjoying their current life, living day by day, and making the best of it.

Patients also experienced feelings of happiness or hopefulness. For instance, finding a kidney donor, and donor kidney longevity evoked happiness and gratitude for several patients:

That I am happy that my kidney has been functioning well so far and that I have been so fortunate to find a living donor who gave me one of her kidneys. (Woman, KTx, 54y)


Hope was also experienced by patients: some hoped their donor kidney would function well for a long time, while others held on to a general sense of hope regarding their future:

Hopefully positive. 'Glass half full.' (Man, KTx, 68y)

Finally, it should be noted that the themes reflect the range of emotions patients mentioned, and that some patients also described a mixture of positive and negative emotions.

3

Figure 1. Visual representation of the findings for research question one



## Table 2. Illustrative quotes per (sub)theme for research question one: How do patients with chronic kidney disease view their future?

### Navigating an uncertain future and emotional challenges Uncertainty

- It could all be different again. (Man, KTx, 59y)
- I wonder what is going to come my way. This mainly involves uncertainty and sadness. (Woman, CKD without KRT, 48y)
- The uncertainty about the future, whether I will have to start dialysis and whether a donor kidney will be available for me at that time! (Man, CKD without KRT, 51y)
- The uncertainty about how long my donor kidney will last? (Woman, KTx, 72y)
- What if... my donor kidney stops, what would I want then... uncertain feeling. (Woman, KTx, 62y)

### Fear of what is to come

- I am very scared. (Woman, CKD without KRT, 79y)
- Sometimes fear of how long the kidney will continue to function well. (Woman, KTx, 49y)
- Fear of kidney rejection. (Woman, KTx, 69y)
- What if my kidney fails, this is my second donor kidney. Quality of life will not improve. The fear that I will not grow old. (Woman, KTx, 51y)
- Uncertainty, afraid of death. (Woman, CKD without KRT, 64y)
- Fear of new medication routines and the structure/restrictions that come with it.
   (Woman, CKD without KRT, 31y)

### Sadness about the future

- Sadness about having to go back to dialysis (Man, KTx, 63y)
- Sadness over things I can no longer do or am allowed to do (Woman, CKD without KRT, 31y)

### Other emotional challenges

- Furious. (Woman, CKD without KRT, 51y)
- Resentment towards the general practitioner. (Man, KTx, 59v)
- Vulnerability (Man, KTx, 67y)

### Neutrality and emotional equilibrium

- Given the stable course of my disease, currently I do not have major worries. (Man, CKD without KRT, 40v)
- None. I want to make the best of it. It doesn't make me emotional. (Man, dialysis, 83y)
- Nothing special. (Man, KTx, 75y)

### Positive feelings regarding the future with CKD

### Calmness

- I resign myself to it. (Woman, dialysis, 89y)
- For now, I am calm and have reasonable trust in my body. (Woman, KTx, 57y)
- Acceptance! (Man, dialysis, 77y)

- No stress. (Man, KTx, 70y)
- After finding a donor, I felt more peace of mind and greater confidence in the future. Now that I seem to be stable for a while, after medication and lifestyle changes, I am less focused on the future because the current stress is less present. (Woman, CKD without KRT, 60y)
- Seize the day! (Woman, dialysis, 71y)
- I want to make the best of it. (Man, dialysis, 83y)
- I try to live day by day and enjoy every day. (Man, dialysis, unknown age)

### Happiness and gratitude

- Mainly that I am happy with the transplanted kidney I received. (Man, KTx, 70y)
- Feelings of gratitude and joy that it has been going well for over thirty years. (Man, KTx, 38y)
- Having received three transplants makes me very grateful and motivates me to handle this with great care. (Man, KTx, 73y)

### Hope

- It's not a pleasant outlook, but acceptance and hope are also part of it. (Woman, dialysis, 71y)
- A sense of hope (that the transplanted kidney will continue to function well). (Woman, KTx, 50y)
- I hope for a lot of luck to keep my new kidney functioning for a long time. (Man, KTx, 51y)

The first research question was answered using the following question from the survey: "What emotions do you experience when you think about your future with a chronic kidney disease?"

# What are the prognostic needs of patients regarding their future with CKD? (RQ2)

Many patients shared that they discuss 'the future' with healthcare professionals, covering a wide array of medical topics, such as treatment options, medication, physical symptom management, disease progression and prognosis. Only a few patients stated to discuss emotional and social consequences of CKD with healthcare professionals, like the impact on relationships, work participation, quality of life and mental health. The majority of patients shared a general wish for more personalized prognostic information on a variety of topics. Below, the three main themes are discussed, with corresponding subthemes and illustrative quotes (see Figure 1 and Table 3).

### Wish for more personalized prognostic information on CKD treatment

Patients mentioned being particularly interested in receiving personalized prognostic information about different treatment options, including dialysis, the risk of rejection and durability of their donor kidney, and the possibilities and timeline of receiving a kidney transplantation:

How long do I have to wait now that I am on the donor list? (Woman, dialysis, 44y)

Furthermore, thinking back to two years ago, they would have appreciated knowing more about their kidney graft. For instance, the durability of their donor kidney, whether they could have prevented chronic rejection, and the consequences of human leukocyte antigen (HLA) mismatches:

The consequences of having many HLA mismatches on kidney survival. This has simply been discussed little or not at all with me. (Woman, KTx, 67y)

Some patients were curious about the possibilities of different dialysis modalities, such as nightly dialysis or home dialysis, how long they can dialyze until a kidney donor comes available, or how to best prepare for dialysis. Others were interested in understanding the timeframe before dialysis and strategies to delay it:

How long can I go without dialysis, and what can I do to postpone it as long as possible? (Woman, CKD without KRT, 79y)

Patients were also seeking answers about their future medication regimen. They wondered whether they could stop taking certain immunosuppressive medications and what side effects to expect:

What is the prognosis regarding the side effects of the medications? And what additional issues can I expect in the long term related to the prolonged use of anti-rejection medication? (Woman, KTx, 66y)

Reflecting on the past years, many patients wished they had known more about the long-term consequences and side effects of immunosuppressive medication.

Patients also expressed an interest in the latest developments in CKD treatments, such as less burdensome dialysis techniques and medication, or innovative technologies like a portable artificial kidney:

When will a portable artificial kidney be available? (Man, dialysis, 83y)

### Seeking prognostic insight into future outcomes

Many patients were interested in gaining more insight into their prognosis, mainly how their kidney function will deteriorate in the future:

What the future might look like: deterioration of kidney function. (Woman KTx, 61y)

Patients also wanted to know more about strategies to slow down CKD progression. Patients asked several questions on how they could influence their prognosis by making lifestyle changes:

How long can I maintain my physical form through diet and lifestyle? (Man, dialysis, 83y)

Patients shared many questions about their overall health status in the future. Not only did they wonder what to expect in terms of their life expectancy with CKD, but also which symptoms they might experience in the future:

What symptoms can I expect? (Woman, CKD without KRT, 62y)

Additionally, patients were concerned about their societal and social roles, such as their ability to work/volunteer and travel:

Can I keep working? Can I continue to function? What should I do to be able to travel to a distant country, for example? (Woman, CKD without KRT, 60y)

### No need for more prognostic information

Some patients did not want to know more about their future. For example, some patients felt like they already had sufficient information about their future with CKD. Patients either read about CKD themselves or felt like they were adequately informed by their healthcare professionals:

I do not have any more questions about it; I am very well prepared and have received information from the LUMC about the future. (Woman, KTx, 69y)

Some patients preferred not to delve into the future and its uncertainties too much, and preferred to live in the present moment instead:

I have already had to endure so many unpleasant (medical) things that I prefer to live in the present. This will probably only get worse in the future. (Woman, KTx, 55y)

A few patients acknowledged the unpredictability of the future and emphasized they preferred to deal with any hurdle as it arises:

Actually nothing. I often find it difficult to look into the future; it is unpredictable anyway. I prefer to adapt to situations as they come. (Man, KTx, 64y)

Illustrative quotes Kidney transplantation Feeling well-informed The future cannot be Symptoms and life Self-management Life participation Kidney disease **Embracing the Future medical** Subthemes Figure 2. Visual representation of the findings for research question two progression innovations Medication unknown predicted Dialysis prognostic information prognostic information Seeking prognostic insight into future No need for more on CKD treatment Main themes Wish for more personalized outcomes regarding their future with What are the prognostic questions of patients Research question CKD

# Table 3. Illustrative quotes per (sub)theme for research question two: What are the prognostic needs of patients regarding their future with chronic kidney disease?

### Wish for more prognostic information on CKD treatment

### Kidney transplantation

- Possibility of a potential new transplant. (Man, KTx, 67y)
- How long will my donor kidney last? (Woman, KTx, 70y)
- Is a transplant possible? What are the conditions? (Man, dialysis, 75y)
- Risk of rejection. (Woman, KTx, 61y)
- When will I receive a kidney? (Man, CKD without KRT, 52y)

### **Dialysis**

- Night dialysis; what are the possibilities. (Woman, CKD without KRT, 63y)
- What are the options if I ever have to start dialysis again, and do I still want that? (Woman, KTx, 56y)
- How long can I continue dialysis until a new donor becomes available? (Woman, dialysis, 64y)
- Does home dialysis exist, and what does it entail? (Man, CKD without KRT,75y)

#### Medication

- Optimizing medications to reduce side effects. (Woman, KTx, 61y)
- Whether I can stop taking medications. (Woman, CKD without KRT, 63y)
- Are there any expected changes in the medication policy? (Woman, KTx, 57y)
- What can I expect regarding medications? (Woman, CKD without KRT, 62y)

### **Future medical innovations**

- Possible technological advancements in treatments. (Woman, dialysis, 71y)
- Progress in the development of cures for kidney diseases. (Woman, KTx, 69y)
- New, less burdensome medications. (Man, KTx, 70y)
- Waiting for future developments in dialysis. (Man, dialysis, 77y)
- Whether by the time I need to start dialysis, it might be a more pleasant experience, with fewer side effects, so that the rest of life can be more comfortable than how people currently feel after treatment. (Man, CKD without KRT, 51y)

### Seeking prognostic insight into future outcomes

### Kidney disease progression

- How long will my kidneys continue to function adequately? (Man, CKD without KRT, 75y)
- Expected duration of good kidney function. (Man, KTx, 54y)
- How long can I continue to live with my own kidneys? (Man, CKD without KRT, 66y)

### Self-management

- I would like to know if I can take more specific measures myself, for example in terms of diet, to maintain my health with the kidney as well as possible. (Woman, KTx, 65y)
- What is the best I can do for the highest chance of a long life? (Man, KTx, 79y)
- What can I do to keep my body as healthy as possible? (Woman, KTx, 54y)

 Is there anything that can be done to slow down the procession? (Woman, CKD without KRT, 56y)

### Symptoms and life expectancy

- What symptoms can I expect? (Woman, CKD without KRT, 62y)
- How long do I have left? (Man, KTx, 78y)
- How old can I become? (Woman, CKD without KRT, 31y)
- How long will I live this way? (Man, CKD without KRT, 67y)
- How long can I continue to live relatively problem-free? (Woman, CKD without KRT, 48y)

### Life participation

- How long can I continue with my volunteer work? (Man, dialysis, 83y)
- Financial security. (Man, KTx, 38y)

### No need for more prognostic information

### Feeling well-informed

- I already know a lot. (Man, KTx, 78y)
- I have a general idea of what to expect. I read about this myself. (Woman, KTx, 40y)
- I am fairly informed about what the future holds for me. (Man, CKD without KRT, 83y)

### **Embracing the unknown**

- I don't know, I just experience it as it comes. (Man, dialysis, 86y)
- I don't want to know, because then I would plan my entire future around it. (Man, KTx, 70y)
- Strangely, nothing. I manage well living day by day. (Man, KTx, 74y)

### The future cannot be predicted

- Nothing: no one can predict the future. I am stable. (Woman, KTx, 67v)
- It has been going well for 31 years. The future is unpredictable anyway. (Woman, KTx, 66y)
- Unfortunately, it cannot be predicted. (Woman, dialysis, 70y)

The second research question was answered using the following questions from the survey: "What would you like to know about your future with a chronic kidney disease?", and "If you think back to a year or two ago, what would you have wanted to know about your life with a chronic kidney disease now?"

### Discussion

In this qualitative study, we aimed to explore the following two research questions: 1) How do patients with CKD view their future? and 2) What are the prognostic needs of patients regarding their future with CKD? These questions address an important knowledge gap in understanding CKD patients' future perspectives and prognostic needs. While more research now focuses on the development of prognostic models to predict the risk of various outcomes, it remains unclear what patients prefer regarding this prognostic information.

Regarding patients' perspectives on the future, we found an array of emotional responses, from negative emotions like uncertainty, fear and sadness to positive ones like calmness, hope, and trust. Prognostic uncertainty in CKD poses considerable challenges, as supported by literature linking this uncertainty to anxiety, depressive symptoms and lower health-related quality of life. (27, 28) Interestingly, these negative emotions can serve a dual role: while burdensome, they may also be motivators for self-management, encouraging patients to find ways to delay disease progression. (29) Excessive fear or uncertainty, however, can become overwhelming and paralyzing. (30-33) Conversely, positive emotions, such as hope and trust, may serve as a psychological anchor, helping patients to deal with CKD-related uncertainties. (15, 34) Our findings underscore that acceptance plays an important role in maintaining a positive outlook, which aligns with previous research highlighting acceptance as a key coping strategy in CKD patients. (35) Moreover, psychological treatments that focus on acceptance, such as Acceptance and Commitment Therapy (ACT) have been shown to improve treatment adherence and reduce symptoms in dialysis patients. (36, 37)

Additionally, some patients experience neither positive nor negative emotions, but rather a form of neutrality regarding their future. For some, this neutrality stems from stability of their disease, reducing concerns about the future. For others, it reflects emotional adjustment to and acceptance of the disease and associated challenges. Neutrality may serve as a coping mechanism, allowing patients to remain balanced and in control. (35) Finally, many patients experience a mixture of positive *and* negative emotions.

This wide variety and interplay of emotions reflects the psychological complexity of having CKD. (16, 33) This complexity can only be better understood through open conversations with patients, allowing healthcare professionals to gain awareness of the emotional challenges for patients with CKD. A holistic, patient-centred approach to nephrological care can encourage patients to engage more actively in shared decision-making and self-management, and can enhance mental and physical health outcomes. (14, 38, 39)

Regarding prognostic needs, patients desired more personalized prognostic information on treatment strategies, including kidney transplantation, dialysis and medication. Although these topics are commonly discussed with healthcare professionals, it seems that these discussions sometimes lack detail and are not (sufficiently) tailored to the individual. Additionally, patients were interested in medical advancements (e.g., a portable artificial kidney or medication with less side effects), reflecting their hope for medical innovations and less burdensome treatment options. (40, 41)

Patients also sought more information about prognostic outcomes such as CKD progression, life expectancy, and quality of life. A notable finding was the wish for more practical guidance on self-management strategies to prevent or slow down CKD progression. In order to actively engage in self-management, patients need knowledge on what they can do and how to do it. (42) The importance of self-management in CKD is increasingly recognized and literature shows that self-management interventions can indeed improve long-term outcomes. (43, 44)

However, not all patients want to know more about what the future holds. Some patients feel sufficiently informed about their future, either by their healthcare providers or by the information they have sought out themselves. Others prefer to live in the present moment, as the future with CKD likely holds many unexpected challenges. Previous studies suggest that maintaining uncertainty may facilitate hope, especially when the alternative is negative certainty. (45) To maintain this uncertainty, patients may adopt coping strategies like avoidance, selective ignoring and neutralizing. (46) While these strategies might preserve short-term hope, they can also hinder patients from proactively engaging in self-management. At the same time, there is something to be said for living in the moment and learning to coexist with uncertainty, which can be an important aspect of psychological adaptation. Importantly, patients should have a say in how much prognostic information they receive, and considering these preferences is crucial in patient-centred care.

Thus, despite conversations about the future taking place between healthcare professionals and CKD patients, there remain unmet prognostic information needs. Our findings underscore the diversity and individuality of these prognostic needs, which is in line with our previous survey study showing that prognostic information needs differ based on CKD stage, gender and age. (17) Future research should focus on how healthcare professionals can facilitate these discussions about the future and how prognostic information can be tailored to the individual patient. Exploring the potential of digital tools for this purpose may also be valuable. (47) Furthermore, the relationship between patients' emotional responses and coping strategies, and their prognostic information needs should be explored, providing more detailed guidance for personalized care.

To our knowledge, this study is among the first to delve further into the future perspectives and prognostic needs of patients with CKD. A strength of this study is that we included patients from all stages of CKD to offer a broad perspective on this topic, and the large sample for a qualitative study. However, this study also has some limitations. First, only patients from Dutch patient associations and hospitals were included, and the survey was only available in Dutch. Therefore, transferability of results to other patient groups (e.g., who do not speak the Dutch language) and other countries, is limited. Second, researchers' preconceptions, experiences and expectations may have coloured the interpretation of results. To address this, a group of researchers with a diverse background were involved throughout the course of this study. Third, we used open-ended survey questions, which do not allow for the same depth of exploration as is possible in interviews. Finally, some questions required patients to reflect on what they would have wanted to know earlier in their disease trajectory. This retrospective assessment introduces potential recall bias, as patients' current perspectives may not accurately reflect their earlier perspectives.

### Conclusion

To conclude, patients with CKD experience a wide variety of emotions regarding their future, and despite conversations about the future taking place in nephrological practice, there remain unmet questions regarding the future. While many patients expressed a wish for more personalized prognostic information on several topics, others preferred to avoid gaining more knowledge on their future. These results underline the importance of adopting a personalized approach to prognostic information provision for patients with CKD, acknowledging and taking into account the diverse emotional responses and individual preferences of patients.

### References

- 1. Shirazian S, Aina O, Park Y, Chowdhury N, Leger K, Hou L, et al. Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis. 2017;10:11-26.
- 2. Combs SA, Teixeira JP, Germain MJ. Pruritus in Kidney Disease. Semin Nephrol. 2015;35(4):383-91.
- 3. Gregg LP, Bossola M, Ostrosky-Frid M, Hedayati SS. Fatigue in CKD: Epidemiology, Pathophysiology, and Treatment. Clin J Am Soc Nephrol. 2021;16(9):1445-55.
- 4. Davison SN, Jhangri GS. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage. 2010;39(3):477-85.
- 5. Gela YY, Tesfaye W, Melese M, Getnet M, Ambelu A, Eshetu HB, et al. Common mental disorders and associated factors among adult chronic kidney disease patients attending referral hospitals in Amhara Regional State. Scientific Reports. 2024;14(1):6812.
- 6. Cwiek A, Czok M, Kurczab B, Kramarczyk K, Drzyzga K, Kucia K. Association between depression and hemodialysis in patients with chronic kidney disease. Psychiatr Danub. 2017;29(Suppl 3):499-503.
- 7. Cogley C, Bramham J, Bramham K, Smith A, Holian J, O'Riordan A, et al. High rates of psychological distress, mental health diagnoses and suicide attempts in people with chronic kidney disease in Ireland. Nephrol Dial Transplant. 2023;38(10):2152-9.
- 8. Wang CJ, Cukor D, Johansen KL. Sexual Dysfunction Among Patients With Chronic Kidney Disease. Seminars in Nephrology. 2021;41(6):534-49.
- 9. Al-Mansouri A, Al-Ali FS, Hamad AI, Mohamed Ibrahim MI, Kheir N, Ibrahim RA, et al. Assessment of treatment burden and its impact on quality of life in dialysis-dependent and predialysis chronic kidney disease patients. Res Social Adm Pharm. 2021;17(11):1937-44.
- 10. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-96.
- 11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
- 12. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331-40.
- 13. Lopez-Vargas PA, Tong A, Phoon RK, Chadban SJ, Shen Y, Craig JC. Knowledge deficit of patients with stage 1-4 CKD: a focus group study. Nephrology (Carlton). 2014;19(4):234-43.
- 14. de Jong Y, van der Willik EM, Milders J, Meuleman Y, Morton RL, Dekker FW, et al. Person centred care provision and care planning in chronic kidney disease: which outcomes matter? A systematic review and thematic synthesis of qualitative studies: Care planning in CKD: which outcomes matter? BMC Nephrol. 2021;22(1):309.
- 15. Davison SN, Simpson C. Hope and advance care planning in patients with end stage renal disease: qualitative interview study. BMJ. 2006;333(7574):886.
- 16. Tong A, Sainsbury P, Chadban S, Walker RG, Harris DC, Carter SM, et al. Patients' experiences and perspectives of living with CKD. Am J Kidney Dis. 2009;53(4):689-700.
- 17. Milders J, Ramspek CL, Meuleman Y, Bos WJW, Michels WM, Konijn WS, et al. Dealing with an uncertain future: a survey study on what patients with chronic kidney disease actually want to know. Clin Kidney J. 2024;17(8):sfae225.
- 18. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):334-40.

- 19. Colorafi KJ, Evans B. Qualitative Descriptive Methods in Health Science Research. HERD. 2016;9(4):16-25.
- 20. Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, et al. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med. 2021;36(10):3179-87.
- 21. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57.
- 22. Central Committee on Research Involving Human Subjects (CCMO) Legal framework for medical scientific research [Available from: <a href="https://english.ccmo.nl/investigators/legal-framework-for-medical-scientific-research/your-research-is-it-subject-to-the-wmo-or-not">https://english.ccmo.nl/investigators/legal-framework-for-medical-scientific-research/your-research-is-it-subject-to-the-wmo-or-not</a>.
- 23. Dutch Kidney Patients Association. The added value of of patients in research Information for researchers [Available from: <a href="https://www.nvn.nl/media/1137/brochure-rol-van-pati%C3%ABnten-in-onderzoek-onderzoekers">https://www.nvn.nl/media/1137/brochure-rol-van-pati%C3%ABnten-in-onderzoek-onderzoekers</a> eng.pdf.
- 24. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77-101.
- 25. Green J, Thorogood N. Qualitative methods for health research. 2018.
- 26. Clarke V, Lane C. Teaching thematic analysis: Overcoming challenges and developing strategies for effective learning Victoria Clarke & Virginia Braun.
- 27. Cho O-H, Hong I, Kim H. Effect of Uncertainty in Illness and Fatigue on Health-Related Quality of Life of Patients on Dialysis: A Cross-Sectional Correlation Study. Healthcare. 2022;10(10):2043.
- 28. Cheng J, Yang D, Zuo Q, Peng W, Zhu L, Jiang X. Correlations between uncertainty in illness and anxiety, depression and quality of life in patients receiving maintenance haemodialysis: A cross-sectional study. Nurs Open. 2022;9(2):1322-31.
- 29. Jamieson NJ, Hanson CS, Josephson MA, Gordon EJ, Craig JC, Halleck F, et al. Motivations, Challenges, and Attitudes to Self-management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. American Journal of Kidney Diseases. 2016;67(3):461-78.
- 30. Gobeil-Lavoie AP, Chouinard MC, Danish A, Hudon C. Characteristics of self-management among patients with complex health needs: a thematic analysis review. BMJ Open. 2019;9(5):e028344.
- 31. Uzun MB, Gülpınar G, Pehkivanlı A, Şengül Ş. A qualitative study exploring self-management behaviour of patients with chronic kidney disease during COVID-19. Fabad Eczacılık Bilimler Dergisi. 2024;49(2):345-58.
- 32. Cui Y, Guo Z, Yang T, Liu Q, Liu N, Yang H, et al. Network analysis of negative emotion and self-management in Chinese patients with early chronic kidney disease. Current Psychology. 2024;43(11):10237-46.
- 33. Sein K, Damery S, Baharani J, Nicholas J, Combes G. Emotional distress and adjustment in patients with end-stage kidney disease: A qualitative exploration of patient experience in four hospital trusts in the West Midlands, UK. Plos one. 2020;15(11):e0241629.
- 34. Feldman DL, Fuller LJ. The Importance of Hope for Patients With CKD. Am J Kidney Dis. 2024;84(4):A11-A2.
- 35. Subramanian L, Quinn M, Zhao J, Lachance L, Zee J, Tentori F. Coping with kidney disease qualitative findings from the Empowering Patients on Choices for Renal Replacement Therapy (EPOCH-RRT) study. BMC Nephrol. 2017;18(1):119.
- 36. Sadeghi AH, Ahmadi SA, Ghodrati-Torbati A. The effectiveness of acceptance and commitment therapy on clinical symptoms and treatment adherence in dialysis patients. J Educ Health Promot. 2024;13:28.
- 37. Elander J, Stalker C, Arborg M, Coyne E, Kapadi R, Taal MW, et al. Living well on haemodialysis: Feasibility and acceptability trial of an online Acceptance and Commitment Therapy (ACT) programme for people receiving kidney haemodialysis. J Context Behav Sci. 2023;30:41-9.

- 38. Lin M-Y, Liu MF, Hsu L-F, Tsai P-S. Effects of self-management on chronic kidney disease: A meta-analysis. International Journal of Nursing Studies. 2017;74:128-37.
- 39. Lee M-C, Wu S-FV, Hsieh N-C, Tsai J-M. Self-Management Programs on eGFR, Depression, and Quality of Life among Patients with Chronic Kidney Disease: A Meta-Analysis. Asian Nursing Research. 2016;10(4):255-62.
- 40. Ramada DL, de Vries J, Vollenbroek J, Noor N, ter Beek O, Mihăilă SM, et al. Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges. Nature Reviews Nephrology. 2023;19(8):481-90.
- 41. Dolson GM. The Wearable Artificial Kidney. Methodist Debakey Cardiovasc J. 2020;16(4):324-5.
- 42. Boger E, Ellis J, Latter S, Foster C, Kennedy A, Jones F, et al. Self-Management and Self-Management Support Outcomes: A Systematic Review and Mixed Research Synthesis of Stakeholder Views. PLoS One. 2015;10(7):e0130990.
- 43. Lightfoot CJ, Nair D, Bennett PN, Smith AC, Griffin AD, Warren M, et al. Patient Activation: The Cornerstone of Effective Self-Management in Chronic Kidney Disease? Kidney Dial. 2022;2(1):91-105.
- 44. Zimbudzi E, Lo C, Misso ML, Ranasinha S, Kerr PG, Teede HJ, et al. Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: a systematic review and meta-analysis. Systematic Reviews. 2018;7(1):84.
- 45. Mishel MH. Uncertainty in illness. Image J Nurs Sch. 1988;20(4):225-32.
- 46. Breznitz S. The denial of stress. (No Title). 1983.
- 47. van der Horst DEM, van Uden-Kraan CF, Parent E, Bart JAJ, Waverijn G, Verberk-Jonkers I, et al. Optimizing the use of patients' individual outcome information Development and usability tests of a Chronic Kidney Disease dashboard. Int J Med Inform. 2022;166:104838.
- 48. International Standard Classification of Education (ISCED).

## **Supplemental material for Chapter 3**

QR code to English translation of the survey



Table S1. Checklist for Reporting Of Survey Studies (CROSS)\* (1)

| Section/topic              | Item                                                                                              | Item description                                                                                                                                                                                                                                                                                                                                                 | Repor<br>ted             |
|----------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
|                            |                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                  |                          |
|                            |                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                  | page                     |
|                            |                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                  | #                        |
| Title and abstract         |                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                  |                          |
| Title and abstract         | <b>1</b> a                                                                                        | State the word "survey" along with a commonly used term in title or abstract to introduce the study's design.                                                                                                                                                                                                                                                    | 1                        |
|                            | 1b                                                                                                | Provide an informative summary in the abstract, covering background, objectives, methods, findings/results, interpretation/discussion, and conclusions.                                                                                                                                                                                                          | 2-3                      |
| Introduction               |                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                  |                          |
| Background                 | 2                                                                                                 | Provide a background about the rationale of study, what has been previously done, and why this survey is needed.                                                                                                                                                                                                                                                 | 4-5                      |
| Purpose/aim                | 3                                                                                                 | Identify specific purposes, aims, goals, or objectives of the study.                                                                                                                                                                                                                                                                                             | 5                        |
| Methods                    |                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                  |                          |
| Study design               | 4                                                                                                 | Specify the study design in the methods section with a commonly used term (e.g. cross-sectional or longitudinal).                                                                                                                                                                                                                                                | 6                        |
|                            | 5a                                                                                                | Describe the questionnaire (e.g. number of sections, number of questions, number and names of instruments used).                                                                                                                                                                                                                                                 | 6-7                      |
| Data collection<br>methods | 5b                                                                                                | Describe all questionnaire instruments that were used in the survey to measure particular concepts. Report target population, reported validity and reliability information, scoring/classification procedure, and reference links (if any).                                                                                                                     | N.A.                     |
|                            | performed (in the arti<br>method of pretesting,<br>tested, number and d<br>pretesting, and the le | Provide information on pretesting of the questionnaire, if performed (in the article or in an online supplement). Report the method of pretesting, number of times questionnaire was pretested, number and demographics of participants used for pretesting, and the level of similarity of demographics between pre-testing participants and sample population. | 9,<br>suppl<br>emen<br>t |
|                            | 5d                                                                                                | Questionnaire if possible, should be fully provided (in the article, or as appendices or as an online supplement).                                                                                                                                                                                                                                               | suppl<br>emen<br>t       |

| Sample<br>characteristics | 6a  | Describe the study population (i.e. background, locations, eligibility criteria for participant inclusion in survey, exclusion criteria).                                                                                                                                           | 7     |
|---------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
|                           | 6b  | Describe the sampling techniques used (e.g. single stage or multistage sampling, simple random sampling, stratified sampling, cluster sampling, convenience sampling). Specify the locations of sample participants whenever clustered sampling was applied.                        | 7     |
|                           | 6c  | Provide information on sample size, along with details of sample size calculation.                                                                                                                                                                                                  | 8     |
|                           | 6d  | Describe how representative the sample is of the study population (or target population if possible), particularly for population-based surveys.                                                                                                                                    | 7, 20 |
| Survey administration     | 7a  | Provide information on modes of questionnaire administration, including the type and number of contacts, the location where the survey was conducted (e.g. outpatient room or by use of online tools, such as SurveyMonkey).                                                        | 6     |
|                           | 7b  | Provide information of survey's time frame, such as periods of recruitment, exposure, and follow-up days.                                                                                                                                                                           | 7-8   |
|                           | 7c  | Provide information on the entry process:  ->For non-web-based surveys, provide approaches to minimize human error in data entry.  ->For web-based surveys, provide approaches to prevent "multiple participation" of participants.                                                 | 6-8   |
| Study preparation         | 8   | Describe any preparation process before conducting the survey (e.g. interviewers' training process, advertising the survey).                                                                                                                                                        | 6-7   |
| Ethical considerations    | 9a  | Provide information on ethical approval for the survey if obtained, including informed consent, institutional review board [IRB] approval, Helsinki declaration, and good clinical practice [GCP] declaration (as appropriate).                                                     | 6     |
|                           | 9b  | Provide information about survey anonymity and confidentiality and describe what mechanisms were used to protect unauthorized access.                                                                                                                                               | 7-8   |
| Statistical<br>analysis   | 10a | Describe statistical methods and analytical approach. Report the statistical software that was used for data analysis.                                                                                                                                                              | 7-8   |
|                           | 10b | Report any modification of variables used in the analysis, along with reference (if available).                                                                                                                                                                                     | N.A.  |
|                           | 10c | Report details about how missing data was handled. Include rate of missing items, missing data mechanism (i.e. missing completely at random [MCAR], missing at random [MAR] or missing not at random [MNAR]) and methods used to deal with missing data (e.g. multiple imputation). | 7-8   |
|                           | 10d | State how non-response error was addressed.                                                                                                                                                                                                                                         | 7-8   |
|                           | 10e | For longitudinal surveys, state how loss to follow-up was addressed.                                                                                                                                                                                                                | N.A.  |
|                           | 10f | Indicate whether any methods such as weighting of items or<br>propensity scores have been used to adjust for non-<br>representativeness of the sample.                                                                                                                              | N.A.  |
|                           | 10g | Describe any sensitivity analysis conducted.                                                                                                                                                                                                                                        | N.A.  |

| Results                       |     |                                                                                                                                                                                                                                 |                 |
|-------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Respondent<br>characteristics | 11a | Report numbers of individuals at each stage of the study. Consider using a flow diagram, if possible.                                                                                                                           | 8-9             |
|                               | 11b | Provide reasons for non-participation at each stage, if possible.                                                                                                                                                               | N.A.            |
|                               | 11c | Report response rate, present the definition of response rate or the formula used to calculate response rate.                                                                                                                   | 8-9             |
|                               | 11d | Provide information to define how unique visitors are determined. Report number of unique visitors along with relevant proportions (e.g. view proportion, participation proportion, completion proportion).                     | 8-9             |
| Descriptive<br>results        | 12  | Provide characteristics of study participants, as well as information on potential confounders and assessed outcomes.                                                                                                           | 8-9,<br>table 1 |
| Main findings                 | 13a | Give unadjusted estimates and, if applicable, confounder-adjusted estimates along with 95% confidence intervals and p-values.                                                                                                   | N.A.            |
|                               | 13b | For multivariable analysis, provide information on the model building process, model fit statistics, and model assumptions (as appropriate).                                                                                    | N.A.            |
|                               | 13c | Provide details about any sensitivity analysis performed. If there are considerable amount of missing data, report sensitivity analyses comparing the results of complete cases with that of the imputed dataset (if possible). | N.A.            |
| Discussion                    |     |                                                                                                                                                                                                                                 |                 |
| Limitations                   | 14  | Discuss the limitations of the study, considering sources of potential biases and imprecisions, such as non-representativeness of sample, study design, important uncontrolled confounders.                                     | 20              |
| Interpretations               | 15  | Give a cautious overall interpretation of results, based on potential biases and imprecisions and suggest areas for future research.                                                                                            | 20-21           |
| Generalizability              | 16  | Discuss the external validity of the results.                                                                                                                                                                                   | 20              |
| Other sections                |     |                                                                                                                                                                                                                                 |                 |
| Role of funding source        | 17  | State whether any funding organization has had any roles in the survey's design, implementation, and analysis.                                                                                                                  | 22              |
| Conflict of interest          | 18  | Declare any potential conflict of interest.                                                                                                                                                                                     | 22              |
| Acknowledgements              | 19  | Provide names of organizations/persons that are acknowledged along with their contribution to the research.                                                                                                                     | 22              |

<sup>\*</sup>Some elements did not apply to this study due to its qualitative nature.

Although the Consolidated criteria for reporting qualitative studies (COREQ) were originally designed for studies reporting on interviews and focus groups, all applicable components were followed to enhance transparent reporting of this current study. (2)

### **Detailed methods**

### Explanation of the two-phase pilot

The survey was tested during a two-phase pilot: First, three volunteers of the Dutch Kidney Patients Association were invited to share their thoughts on the survey during an online video meeting with two of the authors (JM and CLR). Topics discussed were, amongst others, their general impression of the survey, the included questions, the amount of time it took them to complete the survey and the experienced burden of filling in the survey. Their feedback was incorporated into the first version of the survey. Second, the survey and the accompanying informational letter were sent to two volunteers of the Dutch Kidney Patients Association. The aims of this second phase were to test whether the data gathering in Castor EDC worked well, and to test the overall process of spreading the survey. Furthermore, participants of this second phase also had the opportunity to provide us with any additional feedback during an online video meeting. Again, their feedback was incorporated and the survey was finalized.

### Explanation of the populations (CKD, dialysis and kidney transplantation)

The CKD population was defined as patients that were not undergoing KRT (dialysis or kidney transplantation). The dialysis group consists of patients that were undergoing either haemodialysis or peritoneal dialysis at the time of completing in the survey. Patients that had undergone a kidney transplantation and that were not undergoing dialysis at the time were categorized as kidney transplantation patients for the analyses.

### The survey

The final survey consisted of three main parts: 1) demographics, 2) considerations about the future, and 3) prognostic information. In the first part, participants were asked to provide general information, such as their age, gender, educational level, living situation and treatment type. In the second part, participants were asked if they ever think about their future with CKD and if they discuss this with their nephrologist. Finally, in the last part of the survey, a variety of visual analogue scale (VAS) (0-100, not at all-very much), multiple-choice and open-ended questions were asked to assess to which extent participants wanted to know more about their future with CKD and which specific topics they were interested in regarding their prognosis.

### **References**

- 1. Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, et al. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med. 2021;36(10):3179-87.
- 2. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57.